Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 12, 2026 · Acquisition or asset sale · Investor press release · Financial statements
ROCKET PHARMACEUTICALS, INC.
8
Acquisition or asset sale
Jun 12, 2026
| ItemItem | Disclosure |
|---|---|
| Item 2.01 | Completed an acquisition or asset sale |
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 9.01 | Financial statements and exhibits |
ROCKET PHARMACEUTICALS, INC. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. 1 Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million CRANBURY, NJ – June 12, 2026 – Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announ…
This filing reports Item 2.01 (completed an acquisition or asset sale). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
ROCKET PHARMACEUTICALS, INC. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
